The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Inhibrx Biosciences, Inc. | COM | 45720N103 | 109,713,489 | 1,157,926 | SH | SOLE | 1,157,926 | 0 | 0 | ||
| MeiraGTx Holdings plc | COM | G59665102 | 164,791,427 | 12,197,737 | SH | SOLE | 12,197,737 | 0 | 0 | ||
| Novavax | COM NEW | 670002401 | 64,814,131 | 6,880,481 | SH | SOLE | 6,880,481 | 0 | 0 | ||
| AnaptysBio | COM | 032724106 | 55,479,398 | 821,917 | SH | SOLE | 821,917 | 0 | 0 | ||
| Immuneering Corp | CLASS A COM | 45254E107 | 13,515,709 | 2,708,559 | SH | SOLE | 2,708,559 | 0 | 0 | ||
| Q32 Bio Inc. | COM | 746964105 | 3,109,617 | 244,083 | SH | SOLE | 244,083 | 0 | 0 | ||
| MapLight Therapeutics Inc. | COM | 56565P103 | 32,687,549 | 912,041 | SH | SOLE | 912,041 | 0 | 0 | ||
| Agomab Therapeutics NV | SPONSORED ADS | 00860C102 | 36,124,586 | 2,783,096 | SH | SOLE | 2,783,096 | 0 | 0 | ||
| Odyssey Therapeutics Inc. | COMMON STOCK | 67613T104 | 37,268,786 | 1,991,918 | SH | SOLE | 1,991,918 | 0 | 0 | ||
| First Tracks Biotherapeutics Inc. | ORD SHS | 337185102 | 16,536,970 | 821,917 | SH | SOLE | 821,917 | 0 | 0 | ||